Regenexx’s cover photo
Regenexx

Regenexx

Biotechnology Research

Des Moines, Iowa 9,243 followers

Our Corporate Program helps reduce companies’ orthopedic spend while giving employees a non-surgical option in care

About us

Regenexx was the first to use stem cells from bone marrow concentrate to treat orthopedic injuries, and we've published roughly half of all worldwide research in their application. Through the Regenexx Corporate Program more than 2.000 employer groups have added the Regenexx benefit onto their self-funded health plan. We use our advanced regenerative technologies to help self-funded employers save up to 70% of their orthopedic healthcare costs by providing a non-surgical, lower cost alternative to roughly 70% of elective orthopedic surgeries. Most importantly, the Regenexx benefit gives employees a non-surgical option in care to help reduce pain and improve function that they wouldn’t have covered otherwise. Regenexxx licenses our injectates and processes to a highly skilled network of physicians. Regenexx lab processing routinely achieves 20x concentration of stem cell-containing bone marrow — far above what non-Regenexx processing can achieve. Learn more about the Regenexx approach and how we help employers take control of their health care spend. Visit www.Regenexx.com and www.Regenexxcorporate.com for more information.

Industry
Biotechnology Research
Company size
51-200 employees
Headquarters
Des Moines, Iowa
Type
Privately Held
Founded
2005
Specialties
stem cell, physiatry, sports medicine, Prolotherapy, PRP, diagnostic ultrasound, interventional orthopedics, fluroscopy, regenerative medicine, physician network, fellowship training, prolo, sports medicine, interventional pain medicine, ultrasound, self-insured employers, orthopedic savings, healthcare cost reduction, and healthcare benefits savings

Locations

Employees at Regenexx

Updates

  • Dr. Chris Centeno, Chief Medical Officer and founder of Regenexx, discusses the Regenexx Corporate Program utilization system and InterQual integration for 2025. The Regenexx Corporate Program provides members with an option in care that can reduce the cost of individual orthopedic surgeries by up to 70%. The Regenexx approach addresses a critical gap between non-surgical treatments such as physical therapy and orthopedic surgery. By providing an intermediary option, we help reduce the overuse and misuse of orthopedic surgeries, empowering patients to receive optimal care. For more information about the Regenexx Corporate program and adding the Regenexx benefit to self-funded health plans reach out to one of our Corporate Program sales team members or visit: https://lnkd.in/gt3yVTUe #HealthcareInnovation #Regenexx #InterventionalOrthopedics #20thanniversary #20years #EmployeeBenefits

  • Celebrating 20 years of innovation and transformation in healthcare, Regenexx and its founder, Chris Centeno, M.D., have paved the way in interventional orthopedics for 2 decades. The Regenexx Corporate Program extends this impact to covered lives, with a focus on giving employees a better option in care than orthopedic surgery while simultaneously improving employers' bottom line. It's only the beginning! For insights on interventional orthobiologics, visit www.regenexx.com. To explore the Regenexx Corporate Program, head to www.regenexxcorporate.com. #HealthcareInnovation #Regenexx #InterventionalOrthopedics #20thanniversary Wayne Schellhammer Jason Hellickson

    View profile for Chris Centeno, M.D.

    Chief Medical Officer at Regenexx

    20 years ago, I founded Regenexx. In that time, I've seen countless companies flash bright and disappear in this space, while Regenexx has remained steadfast in its singular mission to make interventional orthobiologics the standard of care alternative to orthopedic surgery. In 2005, I began using both culture-expanded bone marrow MSCs and bone marrow concentrate with PRP. We spent two years doing this for free as part of an IRB-approved study. Since that time, we tested regulatory waters, defined a new field of interventional orthobiologics, and ultimately ended up with more than 3,500 corporate clients who want to use IO to help their employees avoid more invasive surgeries. We've tracked >70,000 patients in a registry, launched two FDA approval trials (one now in phase 2 and one in pre-IND), submitted more patents than I can count, helped launch two 510-K approved devices, and have more than 100 clinical sites which will likely grow to 200 in the next 12 months. We have published dozens of peer-reviewed papers and now even count one of my mentors (Phillippe Hernigou) as part of our team! Thank you to all the employees, scientists, physicians, fundraisers, and others who have helped to take Regenexx from an idea to reality!

    • No alternative text description for this image
  • Just one example of the variety of self-funded clients the Regenexx Corporate Program serves to offer employees a non-surgical solution to their orthopedic pain. Regenexx will be attending the TCA conference March 15th-18th to spread the word to attendees about this incredible benefit! #truckloadstrong #employeebenefits Truckload Carriers Association (TCA)

    View profile for Anthony Vasquez

    regenexx for health plans | ortho/msk benefit solution provider | cost reduction strategies for self-funded health plans

    Regenexx will be at Truckload Carriers Association (TCA) Truckload 2025! Looking forward to connecting with more industry leaders. We currently serve thousands of individuals in the trucking/logistics industry helping them avoid surgery and get back on the road faster.

Similar pages

Browse jobs